Sorry, you need to enable JavaScript to visit this website.

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

A Phase 3b/4, Multi-Center, Double-Blind, Randomized, Parallel Group Study of Tofacitinib (CP-690,550) in Subjects With Ulcerative Colitis in Stable Remission

Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT03281304
Protocol ID: A3921288
PrintDownload
Open Plain Language Summary Result: Click here